What impact will the incoming Trump administration have on the 2017 health care and life sciences regulatory outlook? In this two-part podcast, The New HHS: Tom Price and Value-Based Health Care and The New FDA: Product Development, Pricing and Beyond, Washington, D.C.-based partners Tom Bulleit (health care) and Al Cacozza (life sciences) offer their perspectives on what might lie ahead regarding:

  • Rep. Tom Price's nomination to head HHS
  • Value-based health care
  • Developments at the FDA
  • Drug pricing

To learn more about potential regulatory and enforcement developments emanating from Washington, visit Capital Insights.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.